跳转至内容
Merck
CN
所有图片(2)

主要文件

查看所有文档

安全信息

SML3804

Sigma-Aldrich

PMX205 trifluoroacetate

≥98% (HPLC)

别名:

Hydrocinnamate (HC)-[OP(D-Cha)WR] trifluoroacetate, (5→1)-lactam-N2-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginine trifluoroacetate, HC-[OP(D-Cha)WR] trifluoroacetate, HC-[Orn-Pro-dCha-Trp-Arg] trifluoroacetate, Hydrocinnamate-(L-ornithine-proline-D-cyclohexylalanine-tryptophan-arginine) trifluoroacetate;, Hydrocinnamate-(OPdChaWR) trifluoroacetate, Hydrocinnamate-[OP(D-Cha)WR] trifluoroacetate, PMX 205 trifluoroacetate, PMX-205 trifluoroacetate, c[Arg-Trp-D-Cha-Pro-Orn]-Hca trifluoroacetat

登录查看公司和协议定价
所有图片(2)

About This Item

经验公式（希尔记法）:
C45H62N10O6 · xC2HF3O2
分子量:
839.04 (free base basis)
MDL编号:
MFCD31735786
UNSPSC代码:
51111800
UNSPSC代码:
12352200
NACRES:
NA.21

质量水平

100

方案

≥98% (HPLC)

表单

(Powder or Lyophilized powder or film)

储存条件

desiccated

颜色

white to off-white

储存温度

-10 to -25°C

SMILES字符串

N21[C@@H](CCC2)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCCC[C@@H](C1=O)NC(=O)CCc6ccccc6)CCCNC(=N)N)Cc4c5c([nH]c4)cccc5)CC3CCCCC3

InChI

1S/C45H62N10O6/c46-45(47)49-24-9-18-34-40(57)48-23-10-19-35(51-39(56)22-21-29-12-3-1-4-13-29)44(61)55-25-11-20-38(55)43(60)54-36(26-30-14-5-2-6-15-30)41(58)53-37(42(59)52-34)27-31-28-50-33-17-8-7-16-32(31)33/h1,3-4,7-8,12-13,16-17,28,30,34-38,50H,2,5-6,9-

InChI key

VATFHFJULBPYLM-ILOBPARPSA-N

生化/生理作用

PMX205 is a blood-brain barrier (BBB)-permeable and orally active cyclic hexapeptide that acts as a high-affinity and potent antagonist against complement C5a receptor C5aR1. Unlike its structural analog PMX53, PMX205 is resistant to intestinal metabolism and shows 10-30-times higher in vivo efficacy when administered orally (mortality rate = 1/9 with 0.1 mg/kg/day PMX205 vs. 2/10 with 1 mg/kg/day PMX53 in a rat colitis model) despite similar in vitro potency (PMX205/PMX53 pIC50 = 6.50/6.38 against 50 pM C5a by competitive binding, 9.03/8.24 against C5a-induced human PMN MPO release). PMX205 shows in vivo efficacy in animal models of AD (3-6 mg/kg/day p.o., mice), ALS (1 mg/kg/day p.o., rats), and HD (10 mg/kg/day p.o., rats).

注意

Hygroscopic

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration
Faseb Journal, 20(9), 1407-1417 (2006)
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease
Journal of immunology (Baltimore, Md. : 1950), 183(2), 1375-1383 (2009)
Trent M Woodruff et al.
The Journal of pharmacology and experimental therapeutics, 314(2), 811-817 (2005-05-10)
We have previously shown that complement factor 5a (C5a) plays a role in the pathogenesis of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats by using the selective, orally active C5a antagonist AcF-[OP(d-Cha)WR]. This study tested the efficacy and potency of

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门